| Literature DB >> 29545369 |
William Pao1, Chia-Huey Ooi2, Fabian Birzele2, Astrid Ruefli-Brasse2, Michael A Cannarile3, Bernhard Reis2, Sebastian H Scharf2, David A Schubert2, Klas Hatje2, Nadege Pelletier2, Olivia Spleiss2, John C Reed2.
Abstract
Checkpoint inhibitor therapy has been a breakthrough in cancer research, but only some patients with cancer derive substantial benefit. Although mechanisms underlying sensitivity and resistance to checkpoint inhibitors are being elucidated, the importance of organ-specific regulation of immunity is currently underappreciated. Here, we call for a greater understanding of tissue-specific immunoregulation, namely, "tissue-specific immunostats," to make advances in treatments for cancer. A better understanding of how individual organs at baseline regulate the immune system could enable an improved precision medicine approach to cancer immunotherapy. Cancer Discov; 8(4); 395-402. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh:
Year: 2018 PMID: 29545369 DOI: 10.1158/2159-8290.CD-17-1320
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397